Tocilizumab for KSHV-Associated Multicentric Castleman Disease

NCT01441063 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

NIH

Sponsor class

Conditions

Castleman Disease
Multicentric Castleman Disease
Giant Lymph Node Hyperplasia

Interventions

DRUG: Zidovudine
DRUG: Tocilizumab
DRUG: Valganciclovir (VGC)

Sponsor

National Cancer Institute (NCI)